Literature DB >> 7763170

A 15-year review of esophagectomy for carcinoma of the esophagus and cardia.

K W Millikan1, J Silverstein, V Hart, K Blair, S Bines, J Roberts, A Doolas.   

Abstract

OBJECTIVE: To evaluate the effect of surgical approach and adjuvant therapy on patients with carcinoma of the esophagus and/or cardia.
DESIGN: Retrospective analysis of 157 consecutive patients who underwent esophagectomy.
SETTING: A private university medical center and its affiliated community hospital. PATIENTS: One hundred twenty men and 37 women (mean age, 61.7 years) with carcinoma of the esophagus and/or cardia that was surgically treated between 1978 and 1993.
INTERVENTIONS: Three approaches were used for resection: Transhiatal esophagectomy (THE) (n = 67), transthoracic esophagectomy (TTE) (n = 71), and abdominal-only esophagectomy (AOE) (n = 19). Sixty-five patients received adjuvant radiotherapy and chemotherapy. MAIN OUTCOME MEASURES: Surgical mortality, morbidity, and survival and the effect of adjuvant therapy.
RESULTS: The overall surgical mortality rate was 7.6%: 12.7% with the TTE, 4.5% with the THE, and 0% with the AOE approach. A significantly increased incidence of adult respiratory distress syndrome (P < .001) and empyema (P < .001) was seen with the TTE approach. The average intraoperative blood loss (P = .08) and the median intensive care unit stay (P = .26) and hospital stay (P = .40) were decreased with the THE and AOE approaches when compared with the TTE approach without significance. The overall median survival time was 17 months, with a 5-year survival rate of 21%. There was no significant difference in survival by pathologic stage between approaches. The addition of adjuvant therapy did not affect the overall median survival time or the 5-year survival rate. Node-positive patients did benefit from adjuvant radiotherapy and chemotherapy, with increased median survival times from 7 to 15 months and a 5-year survival rate from 0% to 15% (P = .01).
CONCLUSIONS: The THE and AOE approaches have fewer early complications than does TTE. Both THE and TTE have equal long-term survival rates. Adjuvant therapy provides increased survival to node-positive patients with carcinoma of the esophagus and/or cardia.

Entities:  

Mesh:

Year:  1995        PMID: 7763170     DOI: 10.1001/archsurg.1995.01430060055011

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  16 in total

Review 1.  Thoracoscopic esophagectomy in the prone position.

Authors:  Omar A Jarral; Sanjay Purkayastha; Thanos Athanasiou; Ara Darzi; George B Hanna; Emmanouil Zacharakis
Journal:  Surg Endosc       Date:  2012-03-07       Impact factor: 4.584

2.  Robotic-assisted transhiatal esophagectomy.

Authors:  Carsten N Gutt; Vasile V Bintintan; Jörg Köninger; Beat P Müller-Stich; Michael Reiter; Markus W Büchler
Journal:  Langenbecks Arch Surg       Date:  2006-06-22       Impact factor: 3.445

3.  Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction.

Authors:  Marinke Westerterp; Linetta B Koppert; Christianne J Buskens; Hugo W Tilanus; Fiebo J W ten Kate; Jacques J H G M Bergman; Peter D Siersema; Herman van Dekken; Jan J B van Lanschot
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

4.  Pulmonary Complications due to Esophagectomy.

Authors:  Abulfazl Shirinzadeh; Yashar Talebi
Journal:  J Cardiovasc Thorac Res       Date:  2011-08-20

5.  Decreasing morbidity and mortality in 100 consecutive minimally invasive esophagectomies.

Authors:  Kfir Ben-David; George A Sarosi; Juan C Cendan; Drew Howard; Georgios Rossidis; Steven N Hochwald
Journal:  Surg Endosc       Date:  2011-07-27       Impact factor: 4.584

6.  Minimally invasive esophagectomy: the evolution and technique of minimally invasive surgery for esophageal cancer.

Authors:  Toshitaka Hoppo; Blair A Jobe; John G Hunter
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

7.  Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction.

Authors:  Norihiro Yuasa; Hideo Miyake; Tatsuharu Yamada; Tomoki Ebata; Yuji Nimura; Tatsuo Hattori
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

8.  Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection.

Authors:  Hiroyasu Igaki; Yuji Tachimori; Hoichi Kato
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

9.  Characteristics of gastric cancer with esophageal invasion and aspects of surgical treatment.

Authors:  Kohei Wakatsuki; Tomoyoshi Takayama; Masato Ueno; Sohei Matsumoto; Koji Enomoto; Tetsuya Tanaka; Yoshiyuki Nakajima
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

10.  Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.

Authors:  Sang-Hee Cho; Ik-Joo Chung; Sang-Yun Song; Deok-Hwan Yang; Jeong-Rae Byun; Yeo-Kyeoung Kim; Je-Jung Lee; Kook-Joo Na; Hyeoung-Joon Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.